Pisumsaponin II



Compound IDCDAMM02036
Common namePisumsaponin II
IUPAC name5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-6-[(4-formyl-9-hydroxy-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl)oxy]-3,4-dihydroxyoxane-2-carboxylic acid
Molecular formulaC48H76O18

Experimental data

Retention time16.67
Adduct[M+Na]+
Actual mz963.501
Theoretical mz963.492
Error9.11
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.2058

Identifiers and class information

Inchi keyFZHTWPLZNXRSGR-UHFFFAOYNA-N
SmilesO=CC1(C)C(OC2OC(C(=O)O)C(O)C(O)C2OC3OC(CO)C(O)C(O)C3OC4OC(C)C(O)C(O)C4O)CCC5(C)C1CCC6(C)C5CC=C7C8CC(C)(C)CC(O)C8(C)CCC76C
SuperclassLipids and lipid-like molecules
ClassPrenol lipids

Pharmacokinetic properties

Number of descriptor values(#stars)14
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)1
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)18
Number of reactive functional groups (#rtvFG)3
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)941.118
Computed dipole moment(dipole)13.172
Total solvent accessible surface area (SASA)1132.52
Hydrophobic component of SASA (FOSA)731.198
Hydrophilic component of SASA (FISA)385.705
Pie component of the SASA (PISA)15.617
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)2487.65
Number of hydrogen bond donors (donorHB)9
Number of hydrogen bond acceptors (accptHB)28.5
Free energy of solvation of dipole (dip^2/V)0.0697455
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0754954
Globularity descriptor (glob)0.783994
Predicted polarizability in cubic angstroms (QPpolrz)81.993
Predicted hexadecane/gas partition coefficient (QPlogPC16)25.369
Predicted octanol/gas partition coefficient (QPlogPoct)58.205
Predicted water/gas partition coefficient (QPlogPw)42.457
Predicted octanol/water partition coefficient (QPlogPo/w)0.159
Predicted aqueous solubility (QPlogS)-3.758
Conformation-independent predicted aqueous solubility (CIQPlogS)-6.345
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-3.294
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.552
Predicted brain/blood partition coefficient (QPlogBB)-4.705
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.189
Predicted skin permeability, log Kp (QPlogKp)-6.845
PM3 calculated ionization potential (IP(ev))9.286
PM3 calculated electron affinity (EA(eV))-0.582
Number of likely metabolic reactions (#metab)12
Prediction of binding to human serum albumin (QPlogKhsa)-1.098
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)306.269
Number of nitrogen and oxygen atoms (#NandO)18
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P29350PTPN6Protein-tyrosine phosphatase 1CT98264SEA
P18031PTPN1Protein-tyrosine phosphatase 1BT16347SEA
P17706PTPN2T-cell protein-tyrosine phosphataseT49156SEA
P06746POLBDNA polymerase beta (by homology)T06958SEA
P13726F3Coagulation factor VII/tissue factorT72702SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P60568IL2Interleukin-2T61698SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P16885PLCG2Phospholipase C-gamma-2T93922SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16347DI0009Acute diabete complication[ICD-11: 5A2Y]P18031PTPN1
T16347DI0062Breast cancer[ICD-11: 2C60-2C6Y]P18031PTPN1
T16347DI0308Obesity[ICD-11: 5B80-5B81]P18031PTPN1
T16347DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P18031PTPN1
T49156DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P17706PTPN2
T06958DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P06746POLB
T72702DI0075Cervical cancer[ICD-11: 2C77]P13726F3
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A

Copyright © 2025